501. The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database.
- Author
-
Spielhagen C, Schwahn C, Möller K, Friedrich N, Kohlmann T, Moock J, Kołtowska-Häggström M, Nauck M, Buchfelder M, and Wallaschofski H
- Subjects
- Adult, Body Weights and Measures, Databases, Factual statistics & numerical data, Dose-Response Relationship, Drug, Dwarfism, Pituitary blood, Dwarfism, Pituitary complications, Female, Follow-Up Studies, Germany, Hormone Replacement Therapy adverse effects, Human Growth Hormone adverse effects, Human Growth Hormone blood, Human Growth Hormone deficiency, Humans, Hypopituitarism blood, Hypopituitarism complications, Insulin-Like Growth Factor I analysis, Male, Middle Aged, Quality of Life, Risk Assessment, Time Factors, Young Adult, Dwarfism, Pituitary drug therapy, Human Growth Hormone therapeutic use, Hypopituitarism drug therapy
- Abstract
Objective: To evaluate the treatment effects of long-term growth hormone (GH) replacement therapy in adults with GH deficiency (GHD) who were followed in KIMS Germany (Pfizer International Metabolic Database), a national surveillance study., Design: The analysis was performed using baseline and long-term data (range: 4-10 years) of 440 consecutively documented patients (216 women and 224 men) with GHD, aged 20 to 49 years, enrolled in KIMS Germany. Serum insulin-like growth factor I (IGF-I), fasting blood glucose, fasting serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) as well as body mass index (BMI), waist circumference (WC) and hip circumference (HC) at baseline and at last visit were studied. Furthermore, QoL-AGHDA score was determined to assess quality-of-life (QoL)., Results: The mean dose of GH over all years was 0.41 mg per day in women and 0.37 mg per day in men. IGF-I and IGF-I SDS levels (standard deviation score) increased significantly (p<0.001) during GH treatment. The QoL-AGHDA score decreased significantly (p<0.001), indicating long-lasting improvement in QoL. In total cholesterol, LDL-C and fasting blood glucose, no significant changes were found. Only six patients developed type 2 diabetes during follow-up. Females and males similarly increased significantly in BMI, WC and HC. During GH treatment, recurrences of pituitary or central nervous system tumours or further de novo neoplasia were reported in 6 or 11 patients, respectively. The number of the most frequently reported GH treatment-associated adverse events was low., Conclusion: These observational data show long-term beneficial effects of GH replacement therapy on QoL and show no significant effects on total cholesterol, LDL-C or BMI, WC and HC. Additionally, our data indicate that GH replacement therapy in adults is well tolerated., (Copyright © 2010 Growth Hormone Research Society. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF